Lexicon Pharmaceuticals (LXRX) EBIT Margin (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly EBIT Margin of 4.72% for Q1 2026, up 203007.0% year-over-year from N/an in Q1 2025, and up 98.25% quarter-over-quarter from 269.07% in Q4 2025.
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) EBIT Margin (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported EBIT Margin for 16 consecutive years, with 4.72% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT Margin rose 203007.0% year-over-year to 4.72%; the TTM figure through Mar 2026 stood at 34.79% (up 53377.0% YoY), while the FY2025 annual figure was 98.21%, up 53600.0% from the prior year.
- EBIT Margin grew to 4.72% in Q1 2026 per LXRX's latest filing, from 269.07% in the prior quarter.
- Across five years, EBIT Margin topped out at 12.94% in Q2 2025 and bottomed at 68591.43% in Q2 2022.
- Historically, EBIT Margin has averaged 10321.92% across 5 years, with a median of 3360.9% in 2024.
- Annual changes were most pronounced in 2023 — EBIT Margin jumped 5338868 bps — and 2025, when it plunged 14579 bps.
- Lexicon Pharmaceuticals' EBIT Margin stood at 68591.43% in 2022, then surged by 91 bps to 6101.44% in 2023, then jumped by 98 bps to 123.28% in 2024, then slumped by 118 bps to 269.07% in 2025, then soared by 98 bps to 4.72% in 2026.
- Business Quant data shows LXRX's EBIT Margin at 4.72% in Q1 2026, 269.07% in Q4 2025, and 85.93% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 | -3,835.26% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3,835.26% |
| Mar 31, 2026 | -4.72% |
| Dec 31, 2025 | -269.07% |
| Sep 30, 2025 | -85.93% |
| Jun 30, 2025 | 12.94% |
| Mar 31, 2025 | -2,034.79% |
| Dec 31, 2024 | -123.28% |
| Sep 30, 2024 | -3,639.60% |
| Jun 30, 2024 | -3,360.90% |
| Mar 31, 2024 | -4,011.77% |
| Dec 31, 2023 | -6,657.69% |
| Sep 30, 2023 | -30,636.42% |
| Jun 30, 2023 | -13,955.84% |
| Mar 31, 2023 | -129,758.33% |
| Dec 31, 2022 | -108,135.71% |
| Sep 30, 2022 | -59,217.95% |
| Jun 30, 2022 | -68,591.43% |
| Dec 31, 2021 | -180,928.57% |
| Sep 30, 2021 | -99,834.78% |
| Jun 30, 2021 | -7,674.79% |